Skip to main content

Drug Interactions between calcium carbonate and IBgard

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

calcium carbonate peppermint oil

Applies to: calcium carbonate and IBgard (peppermint oil)

ADJUST DOSING INTERVAL: Administration of enteric-coated, gastro-resistant formulations of peppermint oil (e.g., delayed or sustained release capsules) concurrently with antacids may cause premature dissolution of the enteric coating and early release of the peppermint oil, which could lead to gastrointestinal irritation and reduced therapeutic effects. The use of other medications that can reduce gastric acid, such as H2-receptor antagonists and proton pump inhibitors, may also cause similar issues.

MANAGEMENT: Acid-lowering medications should not be administered at the same time as enteric-coated, gastro-resistant formulations of peppermint oil. In general, H2-receptor antagonists and proton pump inhibitors should preferably be avoided, while antacids should be administered at least 2 hours before or 2 hours after the peppermint oil preparation. The labeling for the specific product should be consulted for administration recommendations and other guidance.

References (2)
  1. (2021) "Product Information. Colpermin IBS Relief (peppermint oil)." Johnson & Johnson Ltd
  2. (2023) "Product Information. Buscomint (peppermint oil)." Opella Healthcare UK Ltd

Drug and food interactions

Moderate

calcium carbonate food

Applies to: calcium carbonate

ADJUST DOSING INTERVAL: Administration with food may increase the absorption of calcium. However, foods high in oxalic acid (spinach or rhubarb), or phytic acid (bran and whole grains) may decrease calcium absorption.

MANAGEMENT: Calcium may be administered with food to increase absorption. Consider withholding calcium administration for at least 2 hours before or after consuming foods high in oxalic acid or phytic acid.

References (6)
  1. Cerner Multum, Inc. "UK Summary of Product Characteristics."
  2. Canadian Pharmacists Association (2006) e-CPS. http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink
  3. Cerner Multum, Inc. "Australian Product Information."
  4. Agencia Española de Medicamentos y Productos Sanitarios Healthcare (2008) Centro de información online de medicamentos de la AEMPS - CIMA. https://cima.aemps.es/cima/publico/home.html
  5. Mangels AR (2014) "Bone nutrients for vegetarians." Am J Clin Nutr, 100, epub
  6. Davies NT (1979) "Anti-nutrient factors affecting mineral utilization." Proc Nutr Soc, 38, p. 121-8
Moderate

peppermint oil food

Applies to: IBgard (peppermint oil)

ADJUST DOSING INTERVAL: Administration of enteric-coated, gastro-resistant formulations of peppermint oil (e.g., delayed or sustained release capsules) with food may cause premature dissolution of the enteric coating and early release of the peppermint oil, which could lead to gastrointestinal irritation and reduced therapeutic effects.

MANAGEMENT: Enteric-coated, gastro-resistant formulations of peppermint oil should not be taken immediately after eating. These products should preferably be taken 30 to 90 minutes before a meal with water. The labeling for the specific product should be consulted for administration recommendations and other guidance.

References (3)
  1. (2018) "Product Information. Ibgard (peppermint oil)." IM Helthscience llc, 1
  2. (2021) "Product Information. Colpermin IBS Relief (peppermint oil)." Johnson & Johnson Ltd
  3. (2023) "Product Information. Buscomint (peppermint oil)." Opella Healthcare UK Ltd

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer